ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Field-Deployable RotEx-LAMP-LFA Platform for Molecular Triage of HPV-Driven Oncogenesis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Field-Deployable RotEx-LAMP-LFA Platform for Molecular Triage of HPV-Driven Oncogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Persisting as a major global health disparity, HPV16/18-associated cervical carcinogenesis continues to disproportionately affect populations in resource-limited regions with compromised screening infrastructure. While molecular detection of E6/E7 oncogenic transcripts surpasses conventional cytology in clinical specificity, current nucleic acid amplification platforms remain impeded by technical complexity, prolonged turnaround times (>4 h), and substantial per-test costs (>$50) that hinder scale-up in low-income settings. Here, RotEx-LAMP-LFA is presented: an innovative point-of-care system integrating microfluidic nucleic acid extraction, rapid isothermal amplification (30 min at 63 °C), and combined lateral flow detection in a single disposable cartridge. Validated with 69 clinical specimens (19 histology-confirmed SCC, 14 HPV+ precancerous lesions, 15 HPV+ infections, and 21 healthy controls), this sample-to-answer platform achieved 94.74% sensitivity (18/19; 95% CI: 84.72-100%) for invasive carcinoma detection with 100% (36/36; 95% CI: 90.44-99.93%) specificity for non-cancer. In addition, a subset of samples is collected through paired self-sampling to validate consistency with clinician-collected specimens, indicating that this innovative platform shows promise for community-level molecular stratification of persistent and progressive HPV infections. It paves the way for accessible, patient-centered cervical cancer risk reporting, with the potential to reduce psychological burden on patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.